← FDA DRUG APPROVALS

FDA ANDA · ANDA210761

MEDROXYPROGESTERONE ACETATE

Sponsor: SUN PHARM

APPLICATION
ANDA210761
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-24
LATEST ACTION
2021-06-22
ROUTE
INTRAMUSCULAR, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

MEDROXYPROGESTERONE ACETATEDiscontinued
MEDROXYPROGESTERONE ACETATE 150MG/ML · INJECTABLE · INJECTION

Approval history

2021-06-22Labeling · Supplement 8 · standardAP
2021-06-22Labeling · Supplement 9 · standardAP
2019-04-24UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →